Search

Displaying results 591 - 600 of 10000 in total
  1. Drug

    Atenolol

    go.drugbank.com/drugs/DB00335
    ApprovedInvestigational

    Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981. … [A235860,A235865] A meta-analysis of over 145,000 patients showed the risk of stroke in patients taking atenolol may depend on the age of the patient.

    Mixtures: ATENOLOLO CLORTALIDONE EG, ATENOLOLO CLORTALIDONE EGProducts: ATENOLOLO EG
  2. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. … However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.

  3. Drug

    Rivaroxaban

    go.drugbank.com/drugs/DB06228
    ApprovedInvestigational

    FDA approved on July 1, 2011. … Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary.

    Products: RIVAROXABAN EG, RIVAROXABAN EG STADA
  4. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in

  5. Drug

    Captopril

    go.drugbank.com/drugs/DB01197
    ApprovedInvestigational

    Captopril may be used in the treatment of hypertension.

    Mixtures: CAPTOPRIL E IDROCLOROTIAZIDE HEXAL, CAPTOPRIL E IDROCLOROTIAZIDE SANDOZCategories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.

  7. Drug

    Teriparatide

    go.drugbank.com/drugs/DB06285
    ApprovedInvestigational

    [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic … [A251395] Teriparatide is used in the treatment of osteoporosis in men and women.[L42590, L42595]

    Products: SONDELBAY (Teriparatide) 20 micrograms/ 80 microliters solution for injection in pre-filled pen, Teriparatid ratiopharm 20 Mikrogramm/80 Mikroliter Injektionslösung in einem vorgefüllten Injektor
  8. Drug

    Ulipristal

    go.drugbank.com/drugs/DB08867
    ApprovedInvestigational

    debated due to ethical concerns related to abortion (Rosato et al, 2016). … A recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily

  9. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].

    Mixtures: SITAGLIPTIN E METFORMINA GALENICUM, SITAGLIPTIN E METFORMINA GALENICUMCategories: Drugs Used in Diabetes